The FDA has approved Zepbound (tirzepatide) for treating moderate to severe obstructive sleep apnea (OSA) in adults with obesity. The drug, coupled with a calorie-deficit diet and increased physical activity, significantly reduces apnea events and body weight. Side effects include nausea, diarrhea, and potential thyroid tumors. Contraindications include personal or family history of certain cancers and severe allergic reactions. The FDA has approved Zepbound (tirzepatide) for treating moderate to severe obstructive sleep apnea (OSA) in adults with obesity. The drug, coupled with a calorie-deficit diet and increased physical activity, significantly reduces apnea events and body weight. Side effects include nausea, diarrhea, and potential thyroid tumors. Contraindications include personal or family history of certain cancers and severe allergic reactions. Health and Fitness, Health Tips, Exercises & Workout Tips, Diet & Wellness | Times of India Lifestyle
